

April 10 2018

## Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

**Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free survival (PFS) in metastasizing colorectal cancer (mCRC) patients, treated with 5-FU/folate based therapy has been accepted for presentation at ASCO 2018, taking place 1-5<sup>th</sup> of June in Chicago, USA. The accepted abstract describes a gene expression study conducted by academic researchers collaborating with Isofol Medical.**

Isofol Medical AB (publ) announces that an abstract has been accepted for presentation at this year's annual meeting of American Society of Clinical Oncology (ASCO). The conference will take place on 1-5<sup>th</sup> of June in Chicago and is the summer's epicentre of research and development within oncology. The clinical management team of Isofol will in parallel to the unveiling, will perform meetings, primarily with American Investigators in the planned ISO-CC-007 study.

The approved abstract describes results from a gene expression study aiming to evaluate the influence of gene expression of folate relevant genes on progression-free survival (PFS) in tumours from patients with metastasizing CRC (mCRC), a study that has been conducted by academic researchers collaborating with Isofol.

*"With the hypothesis that arfolitixorin is suitable for all patients irrespective of their genetic capacity to activate folates, the results of the study could offer an insight into the potential outcome of the pivotal study which will be initiated this summer in the same patient population (mCRC)"* says Karin Ganlöv, CMO for Isofol Medical.

The abstract will be released by ASCO on the 15<sup>th</sup> of May, at 5:00 PM EDT.

**For more information, please contact:**

Anders Rabbe, CEO, Isofol Medical AB (publ)  
E-mail: anders.rabbe@isofolmedical.com  
Phone: +46 (0)707 646 500

**About arfolitixorin**

Arfolitixorin is a new drug developed to increase the efficacy of the cytotoxic agent 5-fluorouracil (5-FU) and as a rescue drug after high-dose methotrexate treatment. The active ingredient in arfolitixorin, [6R]-5,10-methylenetetrahydrofolate, is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. Arfolitixorin is suitable for all patients irrespective of their capacity to activate folates since it does not require metabolic activation to exert its effect.

**About Isofol Medical AB (publ)**

Isofol Medical AB (publ) is a drug development company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer). Through a worldwide exclusive license agreement, Isofol holds the rights to develop and commercialise arfolitixorin within oncology with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.

[www.isofol.se](http://www.isofol.se)